Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01643
|
|||||
| Drug Name |
Fluticasone propionate
|
|||||
| Synonyms |
FLUTICASONE PROPIONATE; Flovent; Cutivate; Flixotide; Flonase; Flixonase; Flovent HFA; Flunase; Flutide; Fluspiral; Flusonal; atemur; Flutivate; Fluinol; Axotide; Asmatil; Brethal; Flovent Diskus 50; Flixotide Disks; Flixotide Disk; Flovent Diskus; Flovent Diskus 100; Flovent Diskus 250; Flixotide Inhaler; Trialona; Rinosone; Inalacor; Cultivate; Ubizol; Zoflut; Flixonase Nasal Spray; Flonase Aq; Fluticasonpropionat Allen; Fluticasone (propionate); UNII-O2GMZ0LF5W; CCI-18781; CCI 18781; MFCD00866007; O2GMZ0LF5W
|
|||||
| Indication | Asthma [ICD11: CA23] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C25H31F3O5S
|
|||||
| Canonical SMILES |
CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)SCF
|
|||||
| InChI |
InChI=1S/C25H31F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,19+,22+,23+,24+,25+/m1/s1
|
|||||
| InChIKey |
WMWTYOKRWGGJOA-CENSZEJFSA-N
|
|||||
| CAS Number |
CAS 80474-14-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 500.6 | Topological Polar Surface Area | 106 | ||
| Heavy Atom Count | 34 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
4
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
CHEBI:31441
|
|||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Fluticasone propionate was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.